NXTC vs. IPA, VTVT, RMTI, KRRO, SLS, CLRB, GYRE, DARE, ELDN, and ACXP
Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include ImmunoPrecise Antibodies (IPA), vTv Therapeutics (VTVT), Rockwell Medical (RMTI), Korro Bio (KRRO), SELLAS Life Sciences Group (SLS), Cellectar Biosciences (CLRB), Gyre Therapeutics (GYRE), Daré Bioscience (DARE), Eledon Pharmaceuticals (ELDN), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical preparations" industry.
ImmunoPrecise Antibodies (NASDAQ:IPA) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings.
ImmunoPrecise Antibodies has higher revenue and earnings than NextCure. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.
In the previous week, ImmunoPrecise Antibodies had 7 more articles in the media than NextCure. MarketBeat recorded 7 mentions for ImmunoPrecise Antibodies and 0 mentions for NextCure. ImmunoPrecise Antibodies' average media sentiment score of 1.89 beat NextCure's score of 0.85 indicating that NextCure is being referred to more favorably in the news media.
NextCure received 66 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 87.50% of users gave ImmunoPrecise Antibodies an outperform vote while only 62.39% of users gave NextCure an outperform vote.
NextCure has a net margin of 0.00% compared to NextCure's net margin of -60.23%. NextCure's return on equity of -25.91% beat ImmunoPrecise Antibodies' return on equity.
ImmunoPrecise Antibodies has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, NextCure has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.
ImmunoPrecise Antibodies currently has a consensus target price of $7.00, suggesting a potential upside of 400.00%. NextCure has a consensus target price of $5.50, suggesting a potential upside of 281.94%. Given NextCure's higher possible upside, analysts clearly believe ImmunoPrecise Antibodies is more favorable than NextCure.
5.7% of ImmunoPrecise Antibodies shares are held by institutional investors. Comparatively, 47.8% of NextCure shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by company insiders. Comparatively, 11.9% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
ImmunoPrecise Antibodies beats NextCure on 8 of the 15 factors compared between the two stocks.
Get NextCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
NextCure Competitors List
Related Companies and Tools